Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Earnings Routine +

Telescope Innovations Provides Financial Results of Second Fiscal Quarter 2026

By The Northwire Desk — AI Analysis Apr 13, 2026 · 18:01 TELI · 0.385 Telescope Innovations Corp.
TELI · Price

Executive Summary

  • Telescope Innovations reported Q2 FY2026 revenues of $1.64 million, contributing to a year-to-date gross revenue increase to $4.3 million compared to $2.2 million in the previous year.
  • The company achieved significant operational milestones, including the delivery of a second Self-Driving Laboratory (SDL) to Pfizer and the successful production of battery-grade lithium carbonate via its ReCRFT™ process.
  • Despite revenue growth, the company saw an increase in expenses due to aggressive hiring and product fulfillment costs, resulting in an adjusted EBITA loss of $0.71 million for the quarter.

Key Details

Financial Performance (Q2 FY2026) * Revenues: $1.64 million CAD (compared to $1.00 million in Q2 FY2025). * Expenses: $3.11 million CAD (compared to $1.72 million in Q2 FY2025). * Adjusted EBITA Loss: $0.71 million CAD (compared to a loss of $0.44 million in Q2 FY2025). * Year-to-Date Gross Revenues: $4.3 million CAD (compared to $2.2 million for the same six-month period last year). * Expense Drivers: Increased costs associated with hiring technical, sales, and research staff; parts and travel expenses related to product sales, installation, training, and general sales activity.

Self-Driving Labs (SDL) * Delivered a second SDL unit to Pfizer. * Conducted an SDL inauguration at the Korean Pharmaceutical and Biopharma Manufacturer's Association, supported by Dr. Barry Sharpless, the Acceleration Consortium, and Global Affairs Canada.

Lithium Processing Portfolio * Infrastructure: Secured additional laboratory space adjacent to primary labs at the University of British Columbia for ReCRFT™ (lithium carbonate) and DualPure™ (lithium sulfide) development. * ReCRFT™ Process: Produced battery-grade lithium carbonate from battery recycling streams; a collaboration partner successfully integrated this material into a functional battery cell. * DualPure™ Program: Continuing advancement in partnership with Standard Lithium Ltd.; currently engaged in advanced technical discussions with solid-state battery industry leaders in Asia and North America.

Notable Quotes

  • Henry Dubina, CEO: "Delivering our second Self-Driving Laboratory to Pfizer, expanding internationally, demonstrating lithium battery recycling through our ReCRFT™ process, and expanding our lab infrastructure to grow the lithium portfolio all demonstrate technical proof and strong market demand across our platforms."
Read the original news release →

More from Telescope Innovations Corp.

Jun 16, 2026 · 08:01

Triple-digit pre-earnings run meets a wall of cash burn and a quiet going-concern clause.

Earnings Jun 01, 2026 · 08:01

Physical AI Lab Automation & Lithium Processing

Other Apr 13, 2026 · 17:39

SEDAR Interim Financial Statements

None Mar 16, 2026 · 19:34

Telescope enters development deal with AGI Group

M&A / Property Mar 16, 2026 · 08:02

Telescope Innovations and AGI SDA Launch Technology Development Collaboration

M&A / Property Feb 23, 2026 · 18:19

Telescope installs second self-driving lab at Pfizer

Production / Operations